Zura Bio (NASDAQ:ZURA – Free Report) had its target price decreased by HC Wainwright from $5.00 to $3.00 in a research report ...

HC Wainwright reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research report sent to ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

H.C. Wainwright raised the firm’s price target on Compass Therapeutics (CMPX) to $24 from $10 and keeps a Buy rating on the shares. The company ...

H.C. Wainwright lowered the firm’s price target on I-Mab (IMAB) to $7 from $8 and keeps a Buy rating on the shares. The company continues to ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

H.C. Wainwright analyst Mike Colonnese says the recent selloff in the bitcoin miners “has created a very attractive buying opportunity.” Macro factors will continue to overshadow positive ...

Fintel reports that on April 1, 2025, HC Wainwright & Co. initiated coverage of Rezolve AI (NasdaqGM:RZLV) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...

H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ).The total consideration of ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a Buy recommendation. As of January 19, 2024, the average one-year price ...